$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Science / Discoveries

Nose Drops Restore Memory In Aged Mice Sydney Study

University of Sydney researchers delivered mRNA instructions for the protein BDNF through nose drops and restored learning and memory in aged mice to youthful levels, and treated Alzheimer's-model mice showed no further cognitive decline, according to a study published in Advanced Science on November 18, 2026. The work is preclinical, it has run only in mice, and the team says animal safety studies must come before any human trial.

TML Science DeskNov 19, 5:17 AM ET · 3 min read

Edited and fact-checked by Stephen Sprague

Dr. Maria Bergamasco in the Dr. John and Anne Chong Lab for Functional Genomics, Charles Perkins Center (archive). Photo: Stefanie Zingsheim, University of Sydney.
Summary

Animal safety studies must run before the team can test the drops in people.

Tap a passage. React to the part that matters.

Dr. Maria Bergamasco held a slide up to the light in a Sydney laboratory, and she is the first author of the study. Bergamasco works in the School of Life and Environmental Sciences at the University of Sydney, and the work came out of Professor Greg Neely's laboratory at the Charles Perkins Center. The team took its concept from Daniel Keyes' story "Flowers for Algernon," where scientists raise the intelligence of a laboratory mouse before trying the same intervention on a man.

The drops carry messenger RNA packaged in lipid nanoparticles, and the RNA instructs cells to build brain-derived neurotrophic factor, a protein called BDNF that supports neuron survival, plasticity and memory formation, and nasal delivery uses the connections between the nasal cavity and the brain. The cargo reaches the central nervous system without surgery or injections into the brain or spinal cord, and the mRNA itself rides on the clinically validated BioNTech COVID-19 vaccine backbone. That backbone is repurposed here to produce a therapeutic protein instead of an immune response.

"In aged mice, we saw learning and memory significantly increased, returning animal cognition to its youthful prime," Neely said, and the treated aged animals performed at the level of young mice across standardized tests. The tests covered working memory, spatial memory and object recognition, and the researchers also recorded increased neurogenesis, the formation of new neurons, in the hippocampus. "What's exciting is that this was achieved with a simple noninvasive nasal delivery system that builds on the same underlying mRNA-LNP technology platform many people became familiar with during the COVID-19 pandemic," Neely said.

The Alzheimer's arm of the study used 5XFAD mice, a rapid-onset model carrying mutations tied to the human disease, and those animals received the drops twice a week from two months of age, and pathology is detectable in the model from two months. Cognitive decline is apparent from about four months, and the treated mice showed no further cognitive decline at four months, and the treatment preserved function without reducing amyloid plaques. Neely noted that just under a third of Alzheimer's patients carry serious plaques without dementia and show naturally higher BDNF levels.

First author Bergamasco framed the delivery system as the study's wider claim, and she tied it directly to the vaccine platform. "The success of mRNA vaccines showed these systems can safely deliver genetic instructions to cells," Bergamasco said. "We wanted to see whether we could adapt that technology to deliver beneficial proteins to the brain in a completely noninvasive way," and the author list spans four Sydney units. They are the Dr. John and Anne Chong Lab for Functional Genomics, the School of Life and Environmental Sciences, the Charles Perkins Center and the Faculty of Medicine and Health at the University of Sydney.

"Before we can trial this therapy in patients, we need to perform a series of safety studies in animals," Neely said. "It is a very promising pathway but human noses are different from mouse noses so we will need to test our drugs in humans before we know whether it will work," and the team reports no major side effects in the mice during the study. Neely said the group hopes to move through the safety work and reach human trials within the next two years, because the delivery components have already been used in people.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.